Mikael Dolsten - 05 Mar 2025 Form 4 Insider Report for ROCKET PHARMACEUTICALS, INC. (RCKT)

Role: Director
Signature: /s/ Martin Wilson, as attorney-in-fact for Mikael Dolsten
Issuer symbol: RCKT
Transactions as of: 05 Mar 2025
Transactions value $: $0
Form type: 4
Filing time: 24 Apr 2025, 16:06:21 UTC
Previous filing: 16 Sep 2024
Next filing: 18 Mar 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RCKT	Common Stock	Other	$0	+14,220		$0.000000	14,220	05 Mar 2025	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represent restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will become fully vested on December 31, 2025.
F2	Rocket Pharmaceuticals, Inc. (the "Company") entered into a consulting agreement with the Reporting Person, effective March 3, 2025, for services related to the Company's research and development activities. As part of the compensation for services rendered, the Reporting Person received $125,000 of RSUs valued based on the closing price of the Company's common stock on March 3, 2025, which will cliff vest on December 31, 2025.

Content

Represent restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will become fully vested on December 31, 2025.

Rocket Pharmaceuticals, Inc. (the "Company") entered into a consulting agreement with the Reporting Person, effective March 3, 2025, for services related to the Company's research and development activities. As part of the compensation for services rendered, the Reporting Person received $125,000 of RSUs valued based on the closing price of the Company's common stock on March 3, 2025, which will cliff vest on December 31, 2025.